| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Avanafil dibesylate targets phosphodiesterase-5 (PDE5). It is a selective PDE5 inhibitor with an IC50 of 5.2 nM. It also inhibits PDE1 (IC50 = 53000 nM), PDE2 (51000 nM), PDE4 (5700 nM), PDE6, PDE7 (27000 nM), PDE10 (6200 nM), and PDE11. It has significantly higher selectivity for PDE5 over PDE1, PDE6, and PDE11.
|
|---|---|
| ln Vitro |
In the corpus cavernosum strips of the diabetic group, avanafil (TA-1790) diphenylsulfonate (0.01-1000 µM) can 45% increase the relaxation response brought on by electric field stimulation (1-20 Hz)[2].
In vitro, Avanafil dibesylate is a potent PDE5 inhibitor with an IC50 of 5.2 nM. It inhibits PDE5 with high selectivity over other PDE isoforms. Its specific in vitro potency and selectivity are well-characterized. |
| ln Vivo |
The oral administration of Avanafil (TA-1790) diphenylsulfonate (10 mg/kg) to male rats for 30 days enhances the concentration of angiogenesis and dramatically reduces oxidative stress, bone atrophy, and BMD loss induced by dexamethasone [1]. T2DM rats' erectile response is improved by avanafil (TA-1790) diphenylsulfonate (10 µM; ICI; once for 10 weeks) [2].
In vivo, Avanafil dibesylate is used for the treatment of erectile dysfunction. It has a rapid onset of action, with effects observed as early as 15 minutes after dosing. It has a short elimination half-life of approximately 5 hours. It is available in oral tablet formulations. |
| Enzyme Assay |
Cell-free PDE5 inhibition assays for Avanafil dibesylate use purified PDE5 enzyme. The enzyme is incubated with a substrate (e.g., cGMP or a fluorescent cGMP analog) and varying concentrations of the compound (0.01-1000 nM). Enzyme activity is measured by quantifying the hydrolysis product using a scintillation proximity assay or fluorescence-based assay. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for Avanafil dibesylate use smooth muscle cells or cells expressing PDE5. Cells are treated with the compound at concentrations of 0.1-1000 nM for 1-24 hours. Intracellular cGMP levels are measured by ELISA or mass spectrometry following stimulation with a nitric oxide donor. Cell relaxation is assessed as a functional endpoint.
|
| Animal Protocol |
Animal/Disease Models: Male rat glucocorticoid-induced osteoporosis model (GIOP) [1]
Doses: 10 mg/kg Route of Administration: Oral; Route of Administration: Oral. one time/day for 30 days Experimental Results: Reduction in eNOS, NO, PDE-5, PICP, MDA, CoQ10/CoQ10H and 8-OHdG/108dG levels. Increases levels of cGMP, PKG, cortisol and CTCP. Animal/Disease Models: Male rat glucocorticoid-induced osteoporosis model (GIOP) [1] Doses: 10 mg/kg Route of Administration: Oral; Route of Administration: Oral. one time/day for 30 days Experimental Results: Right femoral trabecular bone thickness and epiphyseal bone width increased. Animal/Disease Models: Male T2DM Sprague Dawley rat [2] Doses: 10 µM Route of Administration: intracavernous injection; once for 10 weeks. Experimental Results: ICP/MAP increased and total ICP value increased after nerve stimulation. In vivo animal experiments for Avanafil dibesylate use rodent models of erectile dysfunction (e.g., cavernous nerve injury models). The compound is administered orally at doses of 0.1-10 mg/kg. Endpoints include intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio. Pharmacokinetic parameters (Cmax, Tmax, AUC) are measured in plasma samples. |
| References |
|
| Molecular Formula |
C29H32CLN7O6S
|
|---|---|
| Exact Mass |
799.186
|
| CAS # |
330784-48-0
|
| Related CAS # |
Avanafil;330784-47-9;(R)-Avanafil;1638497-26-3
|
| PubChem CID |
87800810
|
| Appearance |
Typically exists as solid at room temperature
|
| Source |
Endogenously produced metabolite
|
| tPSA |
251
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
54
|
| Complexity |
825
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl.C1=CC=C(C=C1)S(=O)(=O)O.C1=CC=C(C=C1)S(=O)(=O)O
|
| InChi Key |
DTNQLMYRSLBWLF-SQKCAUCHSA-N
|
| InChi Code |
InChI=1S/C23H26ClN7O3.2C6H6O3S/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32;2*7-10(8,9)6-4-2-1-3-5-6/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30);2*1-5H,(H,7,8,9)/t16-;;/m0../s1
|
| Chemical Name |
benzenesulfonic acid;4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
